Non-Small Cell Lung Cancer
Interventions of Interest: Tyrosine kinase inhibitors: Afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceuticals, Inc.) Erlotinib (Tarceva®, Genentech, Inc. and Astellas Pharma US, Inc.) Gefitinib (Iressa®, AstraZeneca) Immunotherapies targeting the programmed death 1 (PD-1) receptor or its ligand (PD-L1): Atezolizumab (Tecentriq®, Genentech, Inc., Roche Group) Nivolumab (Opdivo®, Bristol-Meyers Squibb Co.) Pembrolizumab (Keytruda®, Merck & Co.) Lung cancer is […]